LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

LLY

718.76

-3.71%↓

JNJ

146.36

-1.52%↓

UNH

312.46

-1.93%↓

ABBV

179.78

-4.69%↓

NVO

64.27

-1.68%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.33

Max

1.41

Põhinäitajad
By Trading Economics
Sissetulek	-6.4M -56M
Aktsiakasum	-0.92
Töötajad	171
EBITDA	7.9M -48M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+225.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2025

Turustatistika
By TradingEconomics
Turukapital	-7.4M 90M
Eelmine avamishind	1.36
Eelmine sulgemishind	1.36

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2025, 23:20 UTC

Tulu

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13. mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13. mai 2025, 23:24 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

13. mai 2025, 23:24 UTC

Market Talk

Tulu

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13. mai 2025, 22:58 UTC

Tulu

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13. mai 2025, 22:37 UTC

Tulu

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13. mai 2025, 22:36 UTC

Tulu

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13. mai 2025, 22:35 UTC

Tulu

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13. mai 2025, 22:34 UTC

Tulu

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13. mai 2025, 22:30 UTC

Tulu

Aristocrat Interim Dividend 44 Australian Cents/Share

13. mai 2025, 22:30 UTC

Tulu

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13. mai 2025, 22:29 UTC

Tulu

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13. mai 2025, 22:28 UTC

Tulu

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13. mai 2025, 21:15 UTC

Tulu

Nu Holdings 1Q Rev $3.2B >NU

13. mai 2025, 21:03 UTC

Peamised uudised

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. mai 2025, 20:32 UTC

Tulu

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. mai 2025, 20:31 UTC

Tulu

Alcon 1Q Sales $2.45B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q Rev $2.47B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q EPS 70c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

225.85% tõus

12 kuu keskmine prognoos

Keskmine 4.79 USD 225.85%

Kõrge 17 USD

Madal 1.5 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.